Pmel17 Antibody (C-2): sc-393094

Pmel17 Antibody (C-2) is a mouse monoclonal IgG2a antibody that detects Pmel17 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Pmel17, also known as gp100, is a melanocyte differentiation antigen that plays a crucial role in the immune response against melanoma by presenting tumor-associated antigens to cytotoxic T lymphocytes. Pmel17 is primarily located in the melanosomes of melanocytes, where Pmel17 is involved in the formation of melanin, the pigment responsible for skin color. The localization of Pmel17 in melanosomes is significant because Pmel17 not only contributes to the pigmentation process but also serves as a marker for identifying melanoma cells, which often exhibit upregulated expression of this protein. Pmel17 is highly glycosylated and undergoes proteolytic cleavage, resulting in a secreted form that can be recognized by various monoclonal antibodies, including NKI-beteb, HMB-50, and HMB-45, making Pmel17 a valuable target for diagnostic and therapeutic applications in malignant melanoma. Anti-Pmel17 antibody (C-2) effectively binds to enhance research and clinical applications, particularly in developing immunotherapies for melanoma.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Pmel17 Antibody (C-2) References:

1. Molecular mapping of epitopes on melanocyte-specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo.  |  Kemp, EH., et al. 2001. Clin Exp Immunol. 124: 509-15. PMID: 11472416
2. The repeat domain of the melanosomal matrix protein PMEL17/GP100 is required for the formation of organellar fibers.  |  Hoashi, T., et al. 2006. J Biol Chem. 281: 21198-21208. PMID: 16682408
3. Dual loss of ER export and endocytic signals with altered melanosome morphology in the silver mutation of Pmel17.  |  Theos, AC., et al. 2006. Mol Biol Cell. 17: 3598-612. PMID: 16760433
4. N-terminal domains elicit formation of functional Pmel17 amyloid fibrils.  |  Watt, B., et al. 2009. J Biol Chem. 284: 35543-55. PMID: 19840945
5. The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma.  |  Chen, Y., et al. 2012. J Biol Chem. 287: 24082-91. PMID: 22613716
6. Identification of an amyloid fibril forming segment of human Pmel17 repeat domain (RPT domain).  |  Louros, NN. and Iconomidou, VA. 2016. Biopolymers. 106: 133-9. PMID: 26394553
7. Monitoring Kinetics of pH-Dependent Aggregation and Disaggregation of the Pmel17 Repeat Domain.  |  Dean, DN. and Lee, JC. 2023. Methods Mol Biol. 2551: 79-93. PMID: 36310198
8. pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL.  |  Adema, GJ., et al. 1996. Br J Cancer. 73: 1044-8. PMID: 8624261
9. Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy.  |  Wagner, SN., et al. 1997. Cancer Immunol Immunother. 44: 239-47. PMID: 9222283
10. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).  |  Kemp, EH., et al. 1998. Clin Exp Immunol. 114: 333-8. PMID: 9844040

The preferred Pmel17 antibody is Pmel17 Antibody (E-7): sc-377325.